Dysport in Post-Surgical Neuralgia

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

November 8, 2019

Study Completion Date

November 8, 2019

Conditions
Chronic Scar Pain
Interventions
DRUG

Lidocaine

0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).

BIOLOGICAL

Botulinum toxin type A

0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).

DRUG

Placebo

Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).

DRUG

Placebo

Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).

Trial Locations (1)

WC1X8QD

St Pancras Clinical Research, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY